Data Sheet (Cat.No.T67930L)

TargetMol

CWI1-2 HCL

Chemical Properties



CAS No. : 2408590-37-2

Formula: C22H18Cl4N6O3

Molecular Weight: 556.23

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	CWI1-2 HCL is an effective IGF2BP2 inhibitor, which can induce apoptosis and differentiation by binding IGF2BP2 and inhibiting its interaction with M6A-modified target transcription, and has therapeutic effects on leukemia.
Targets(IC50)	Apoptosis
In vitro	CWI1-2 (0-1 μM, 24 h) hydrochloride demonstrates significant anti-leukemia efficacy.[1]
In vivo	CWI1-2 hydrochloride (5 mg/kg, i.v., once daily, 7-10 days) significantly delays leukemia onset and prolongs survival in BMT recipient B6.SJL (CD45.1) mice, without significantly affecting body weight.[1]

Solubility Information

Solubility	DMSO: 145 mg/mL (260.68 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 1 mg/mL (1.8 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.7978 mL	8.9891 mL	17.9782 mL
5 mM	0.3596 mL	1.7978 mL	3.5956 mL
10 mM	0.1798 mL	0.8989 mL	1.7978 mL
50 mM	0.036 mL	0.1798 mL	0.3596 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Weng H, et al. The m6A reader IGF2BP2 regulates glutamine metabolism and represents a therapeutic target in acute myeloid leukemia. Cancer Cell. 2022;40(12):1566-1582.e10.